FDA issues new guidelines for transmucosal delivery of pain drug

As of Dec. 29, the FDA has placed every product featuring the transmucosal delivery of fentanyl under a single Risk Evaluation and Mitigation Strategy, also known as REMS. Fentanyl is used to treat cancer-related pain when other medicines don't work. A REMS program guides how a drug is made available to patients to protect their health and limit drug abuse. The decision is expected to help companies such as BioDelivery Sciences International ($BDSI), which makes a product that delivers fentanyl through a film placed on the inside of the cheek, reports MedCityNews.com. Story

Suggested Articles

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.

Kindeva, which produces inhalers, transdermal patches and other medical devices, is expanding operations in the St. Paul, Minnesota, area.